ArticleVaccines2025

Baseline Anti-SARS-CoV-2 IgG and Protection from Symptomatic Infection: Post Hoc Analysis of the SCTV01E Phase 3 Randomized Trial.

Lixin Yan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.